Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Cash from Investing Activities (2024 - 2025)

Xilio Therapeutics' Cash from Investing Activities history spans 2 years, with the latest figure at -$401000.0 for Q2 2025.

  • For Q2 2025, Cash from Investing Activities changed N/A year-over-year to -$401000.0; the TTM value through Sep 2025 reached -$429000.0, changed N/A, while the annual FY2024 figure was -$36000.0, 92.59% up from the prior year.
  • Cash from Investing Activities for Q2 2025 was -$401000.0 at Xilio Therapeutics, down from -$22000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$6000.0 in Q4 2024 and bottomed at -$401000.0 in Q2 2025.